Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mydecine Innovations Group Inc C.MYCO

Alternate Symbol(s):  MYCOF

Mydecine Innovations Group Inc. is a Canada-based biotechnology company. The Company is engaged in developing medications and therapies to address mental health disorders, such as nicotine addiction and posttraumatic stress disorder (PTSD). The Company conducts research and development on second generation compounds in Canada with a focus on developing and commercializing psychedelic-inspired regulated medicines. The Company has two lead 3,4-Methylenedioxymethamphetamine (MDMA) candidates. The Company is channeling its MYCO-005, MYCO-006, and MYCO-007 families of patent-pending second-generation MDMA and Psilocybin analogs through Applied Pharmaceutical Innovation (API). It utilizes artificial intelligence (AI) and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make them accessible to the general public upon Health Canada and Food and Drug Administration (FDA) approval.


CSE:MYCO - Post by User

Comment by Updownsidewayson Dec 16, 2016 9:26pm
101 Views
Post# 25613437

RE:Spin-off

RE:Spin-offThis drop from .30 was expected. Company split assets, so once the NHS value were removed, the NF share price dropped to reflect the loss. If NF was .07 not too long ago for both sides of the operation, and now is only one side, what makes you think it won't go lower? Starting revenues will help support the new price, but don't fool yourselves to think it can't go back below .07 without any substantial news.


madeinhemlo wrote: I have not seen any discussion on the spin off that will occur at the end of the month.  Will we see a price on the new corp.?  And will NF drop in price to reclect this development.  I'd like to see what is going to happen.  I tend to think the price drop from the recent high sucked about 1/2 of the value because it seemed to happen shortly after the announcement.  Eoither way, I thin k the shareholdeers will be well rewarded.  Any thoughts?


Bullboard Posts